Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 9:01 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 4,019 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 3 Clear all

Conditions: Schizophrenia
Interventions: AMG 579, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Glendale, California

Conditions: Healthy Adult Participants, Synaptic Plasticity
Interventions: PET Imaging Scan using [11C]UCB-J; Radiation
Lead sponsor: Beatriz Luna; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: CoronaVirus Disease-2019 (COVID-19)
Interventions: ABBV-47D11, Placebo for ABBV-47D11, ABBV-2B04, Placebo for ABBV-2B04; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 11
States / cities: Glendale, California • Cutler Bay, Florida • Miami, Florida + 8 more

Conditions: Acute Myeloid Leukemia
Interventions: ASTX660, ASTX727; Drug
Lead sponsor: Astex Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 15
States / cities: San Francisco, California • New Haven, Connecticut • Miami, Florida + 11 more

Conditions: Sequelae of; Infection, Post Infection Glomerulonephritis, Post-Infectious Peripheral Neuralgia, Post-Infectious Disorder (Disorder), Post-Infectious Arthritis, Post-Infectious Polyneuritis, Post-Infectious Parkinsonism, Post-Infectious Hypothyroidism, Post Infectious Osteoarthritis, Anxiety Disorders, Depression, Depression, Anxiety, Depression, Bipolar, Insomnia, GERD, Gastro Esophageal Reflux, Hepatitis, Glomerulonephritis
Interventions: PurWet, FurFat, PurApo, PurPhl, PurClo, PurInf, Smoliv; Combination Product
Lead sponsor: All Natural Medicine Clinic, LLC; Other
Eligibility: Not listed
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Unintentional Injury
Interventions: Novel approaches for the design of child resistant closures; Other
Lead sponsor: Michigan State University; Other
Eligibility: 42 Months to 54 Months
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 3
States / cities: East Lansing, Michigan • Haslett, Michigan

Conditions: Sarcoma
Interventions: Ra-223 Dichloride; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 15 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Aplastic Anemia, Leukemia, Myelodysplastic Syndrome
Interventions: Busulfan, fludarabine, & cyclophosphamide with immunosuppression with ATG and cyclosporine., CliniMACS device; Drug · Device
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2017
U.S. locations: 6
States / cities: Boston, Massachusetts • New York, New York • Cincinnati, Ohio + 2 more

Conditions: Kaposi Sarcoma
Interventions: Abemaciclib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hypersensitivity
Interventions: Butenafine HCl 1% (BAY1896425), Positive Control-Sodium lauryl sulfate (SLS), Negative Control; Drug · Other
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Fairfield, New Jersey

Conditions: Healthy Volunteers
Interventions: ASP1617, Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 97 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Glendale, California

Conditions: Angle Class 2 Malocclusion
Interventions: In-office fabricated appliance, Carriere Motion Appliance; Other · Device
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 12 Years to 17 Years
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Fibromyalgia
Interventions: Lifestyle physical activity (LPA), Fibromyalgia education; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Gastroesophageal Reflux, Patient Activation
Interventions: Use of mHealth Question Prompt List app; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Stanford, California

Conditions: Chronic Low Back Pain, Negative Affectivity
Interventions: Antidepressant, Enhanced Fear Avoidance Rehabilitation; Drug · Other
Lead sponsor: Ajay Wasan, MD, Msc; Other
Eligibility: 18 Years to 75 Years
Enrollment: 308 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 3
States / cities: Chestnut Hill, Massachusetts • Rochester, Minnesota • Pittsburgh, Pennsylvania

Conditions: Cocaine Dependence, Cocaine Abuse, Cocaine Addiction, Drug Abuse, Substance Abuse
Interventions: quetiapine fumarate, Matched Placebo, Cognitive-behavioral Therapy; Drug · Behavioral
Lead sponsor: Seattle Institute for Biomedical and Clinical Research; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Solid Tumor
Interventions: ABSK121-NX; Drug
Lead sponsor: Abbisko Therapeutics Co, Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 4
States / cities: La Jolla, California • Detroit, Michigan • Las Vegas, Nevada + 1 more

Conditions: ADHD
Interventions: ADHD Group Curriculum; Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 6 Years to 18 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Neurofibromatoses
Interventions: Part 1 Levulan injection, Part 1 Levulan surface application, Part 1 Levulan surface application twice, Part 1 Levulan surface application twice with microneedling, Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 1, Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 2, Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 3; Drug
Lead sponsor: Harry T Whelan, MD; Other
Eligibility: 18 Years to 90 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous, Non-small Cell Lung Cancer, Non-squamous, Head and Neck Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Prostate Cancer, Melanoma
Interventions: ladiratuzumab vedotin, pembrolizumab; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 27
States / cities: Chandler, Arizona • Los Angeles, California • Santa Rosa, California + 24 more

Conditions: Healthy Participants
Interventions: TBP-PI-HBr; Drug
Lead sponsor: Spero Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Sleep Apnea Syndromes, Inflammation
Interventions: Weight Loss Program, CPAP therapy; Behavioral · Device
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 80 Years
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy Participants
Interventions: LY3154207, Placebo, Itraconazole; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: APOL1-Mediated Kidney Disease
Interventions: AZD2373-Arm 1, AZD2373-Arm 2, Placebo, APOL1 Genotyping Clinical Trial Assay; Combination Product · Device
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 86
States / cities: Alabaster, Alabama • Birmingham, Alabama • Irondale, Alabama + 73 more

Search by objective public record fields.

First-in-Human Study to Evaluate AMG 579 in Healthy Subjects and Patients With Stable Schizophrenia

Effects of Adolescent Synaptic Pruning

Study to Assess Adverse Events and How Intravenous (IV) ABBV-47D11 and IV ABBV-2B04 Given Alone and in Combination Moves Through the Body of Adult Participants With Coronavirus Disease 2019 (COVID-19)

A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)

Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2

Design Factors for Evaluating Child Resistant Packaging

Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma

Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine

Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma

Study to Determine Skin Irritation Potential of an Antifungal Cream Containing Trolamine After Repeated Skin Application (Cumulative Irritation Patch Test)

Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP1617 in Healthy Adult Non-Asian and Japanese Subjects Including Assessment of a Food Effect

Carriere Motion Appliance* Versus In-office Sectional Appliance

Lifestyle Physical Activity to Reduce Pain and Fatigue in Adults With Fibromyalgia

Developing and Testing Mobile Health Question Prompt List in Gastroesophageal Reflux Disease

Treating Negative Affect in Low Back Pain Patients

Quetiapine for the Reduction of Cocaine Use

A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors

Exploring the Group Visit Model for Pediatric ADHD Management in the Medical Home

Phase I Photodynamic Therapy (PDT) for Benign Dermal Neurofibromas (NF1)

A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

A Study to Characterize Single and Repeat Dose Pharmacokinetics of Tebipenem-Pivoxil-Hydrobromide (TBP-PI-HBr) and Its Major Metabolite (SPR1349) in Healthy Participants

The Effects of Obesity and Obstructive Sleep Apnea on Inflammation and Heart Disease

A Study of LY3154207 in Healthy Participants

Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants With APOL1-Mediated Kidney Disease